Craig Eagle
About Craig Eagle
Craig Eagle, M.D., has served as a director of Q/C Technologies (QCLS) since April 16, 2021, and is deemed independent under Nasdaq rules . He is Chief Medical Officer at Guardant Health since 2021 and previously held senior oncology leadership roles at Genentech and Pfizer; his clinical training includes FRACP and FRCPA fellowships after medical school at the University of New South Wales . Note: QCLS’s April–May 2025 proxy stated Dr. Eagle would not stand for reelection at the 2025 annual meeting, yet he is listed as a director signing the company’s S-3 on October 3, 2025 .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Guardant Health (GH) | Chief Medical Officer | 2021–present | Expanded liquid biopsy testing; blood-based screening; NCI research agreement |
| Genentech | Vice President, Oncology | Not disclosed | Oversaw oncology medical programs |
| Pfizer | Multiple oncology leadership roles (UK, Canada, Global Alliances; head Oncology Global Medical & Outcomes) | 2009–2019 | Led development/approvals; growth and M&A; clinical programs for several compounds |
| Royal Prince Alfred Hospital (Sydney) | Heme-oncology and lab hematology training | Not disclosed | FRACP/FRCPA; subsequent basic research on monoclonal antibody |
External Roles
| Organization | Role | Tenure/Status |
|---|---|---|
| Guardant Health | Chief Medical Officer | 2021–present |
| Pierian Biosciences (private) | Director; Chair, Science & Policy Committee | Current |
Board Governance
- Committee assignments: Compensation Committee member (no chair roles) .
- Independence: Board determined Dr. Eagle independent under Nasdaq rules .
- Attendance: Board met/acted 24 times in 2024; each director (including Eagle) attended ≥75% of Board/committee meetings .
- Tenure on QCLS board: Director since April 16, 2021 .
- 2025 annual meeting status: Not standing for reelection (term to end immediately prior to annual meeting); board size reduced from 7 to 6 thereafter .
Fixed Compensation
| Component | 2024 Amount | Notes |
|---|---|---|
| Fees earned (cash) | $92,000 | QCLS director compensation table for 2024 |
| Monthly board retainer (non-executive directors) | $8,000/month | Policy approved March 29, 2019; paid monthly |
| Committee/meeting fees | Not separately disclosed | Narrative indicates cash-only fees; no other director compensation in 2024 |
Performance Compensation
| Metric/Instrument | 2024 Grant | Terms |
|---|---|---|
| Stock awards (RSUs/PSUs) | $0 | No director stock awards for 2024 per table |
| Option awards | $0 | None disclosed for directors in 2024 |
| Performance metrics tied to director pay | Not disclosed | No metrics specified for director compensation |
Other Directorships & Interlocks
| Company | Role | Potential Interlock/Conflict |
|---|---|---|
| Guardant Health | Chief Medical Officer | No QCLS-related party transactions disclosed involving Eagle/Guardant |
| Pierian Biosciences | Director | Private company; no QCLS RPTs disclosed |
Expertise & Qualifications
- Extensive global oncology leadership (Pfizer, Genentech), clinical development, regulatory and payer negotiations, and health outcomes expertise .
- Clinical training and fellowships (FRACP, FRCPA) with oncology/hematology specialization; medical degree from University of New South Wales .
- Board experience and scientific oversight (chairing a science/policy committee at Pierian Biosciences) .
Equity Ownership
- Beneficial ownership: Not listed for Dr. Eagle in the Oct 20, 2025 special proxy’s beneficial ownership table (which enumerates select executives and directors) .
- Pledging/hedging: No pledging or hedging by Dr. Eagle disclosed; related-party note lists other parties but not Eagle .
- Options/RSUs: No director equity awards shown for 2024 .
Governance Assessment
- Independence and attendance: Meets Nasdaq independence; attendance ≥75% in 2024—baseline signals of engagement .
- Compensation alignment: Cash-only director pay in 2024 with no equity grants or performance links suggests limited equity alignment and minimal pay-for-performance at the board level .
- Compensation Committee effectiveness: Committee comprised of independent directors; however, it held 0 meetings and took 0 unanimous written consents in 2024 and engaged no compensation consultants—potentially a weak governance signal during a transformative period .
- Conflicts/related parties: No related-party transactions disclosed involving Dr. Eagle; principal related-party exposure centers on PharmaCyte Biotech and its affiliation with Executive Chairman Joshua Silverman (separate from Eagle) .
- Shareholder signals: On Nov 14, 2025, stockholders approved issuance of >20% new securities, the 2021 Plan share increase to 1,400,000, and a reverse split authorization—context of dilution and capital structure actions that heighten scrutiny of board oversight; these are not specific to Eagle but shape governance expectations .
RED FLAGS to monitor: limited Compensation Committee activity and lack of director equity/metric-based incentives in 2024 ; overall capital actions (dilutive issuance and reverse split) increase the importance of robust independent oversight .